Shinsuke Shiotsu

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Ejection Fraction

Small Cell Lung Cancer

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Takayuki Takeda, Tadaaki Yamada, Yusuke Kunimatsu, Keiko Tanimura, Kenji Morimoto, Shinsuke Shiotsu, Yusuke Chihara, Asuka Okada, Shigeto Horiuchi, Makoto Hibino, Kiyoaki Uryu, Ryoichi Honda, Yuta Yamanaka, Hiroshige Yoshioka, Takayasu Kurata, Takayama Koichi
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers 15 (5) (2023)
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Tadaaki Yamada, Nobuyo Tamiya, Naoko Okura, Takahiro Yamada, Junji Murai, Shinsuke Shiotsu, Takayasu Kurata, Takayama Koichi
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers 15 (20) (2023)
Keiko Tanimura, Takayuki Takeda, Akihiro Yoshimura, Ryoichi Honda, Shiho Goda, Shinsuke Shiotsu, Mototaka Fukui, Yusuke Chihara, Kiyoaki Uryu, Shota Takei, Yuki Katayama, Makoto Hibino, Tadaaki Yamada, Takayama Koichi
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers 15 (17) (2023)
Takayuki Takeda, Tadaaki Yamada, Yusuke Kunimatsu, Keiko Tanimura, Kenji Morimoto, Shinsuke Shiotsu, Yusuke Chihara, Asuka Okada, Shigeto Horiuchi, Makoto Hibino, Kiyoaki Uryu, Ryoichi Honda, Yuta Yamanaka, Hiroshige Yoshioka, Takayasu Kurata, Takayama Koichi
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers 15 (5) (2023)